Abiraterone and other novel androgendirected strategies for the treatment of prostate cancer: a new era of hormonal therapies is borne
Therapeutic Advances in Urology, 06/27/2012
Schweizer MT et al. – More recently, other drugs that act along the androgen signaling pathway, such as orteronel, galeterone, enzalutamide and ARN–509, have shown promise in clinical trials. Some of these are expected to gain FDA approval in the near future.